Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 11;12(3):290.
doi: 10.3390/vaccines12030290.

Study on Varicella-Zoster Virus Antibody Levels among Children Aged 1-7 Years in Changzhou, China

Affiliations

Study on Varicella-Zoster Virus Antibody Levels among Children Aged 1-7 Years in Changzhou, China

Dan Wu et al. Vaccines (Basel). .

Abstract

We aim to understand the varicella-zoster virus (VZV) antibody levels in children after vaccination and to construct VZV-IgG centile curves and reference values for children aged 1-7 years. From September to October 2023, a total of 806 children were recruited according to the time intervals of 1 month, 6 months, 1 year, 2 years, and 3 years after vaccination, as well as age groups. A generalized additive model for location, shape, and scale (GAMLSS) was applied to estimate P3, P10, P25, P50, P75, P90, and P97 centile reference values of VZV-IgG, and 95% reference intervals were calculated. A total of 785 children were included in the analysis, with an overall positivity rate of 70.3%, a median antibody concentration of 192.05 (82.89-571.14) mIU/mL, and a positivity rate of 57.7% for one dose of vaccine and 84.2% for two doses. Antibody positivity rates at 1 month, 6 months, 1 year, 2 years, and 3 years after vaccination were 65.1%, 74.4%, 80.4%, 67.7%, and 63.0%, respectively. The GAMLSS results showed that VZV-IgG had a tendency to increase and then decrease after vaccination, and the second dose of vaccination could significantly increase VZV-IgG. Two doses of varicella vaccine should be administered to children in a timely manner and included in the routine vaccination programs.

Keywords: GAMLSS; VZV-IgG; vaccination; varicella.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of this study; in the collection, analyses, or interpretation of data; in the writing of this manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Research flowchart.
Figure 2
Figure 2
Comparison of seropositivity rates for different doses at each time interval.
Figure 3
Figure 3
Variation in each parameter with age. (ac) refer to the variations with age for μ, σ, and υ, respectively.
Figure 4
Figure 4
Centile curves for VZV-IgG (logarithmic) in children aged 1–7 years.

Similar articles

Cited by

References

    1. Freer G., Pistello M. Varicella-zoster virus infection: Natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol. 2018;41:95–105. - PubMed
    1. Kennedy P.G.E., Mogensen T.H., Cohrs R.J. Recent Issues in Varicella-Zoster Virus Latency. Viruses. 2021;13:2018. doi: 10.3390/v13102018. - DOI - PMC - PubMed
    1. Sakakibara R., Sawai S., Ogata T. Varicella-zoster virus infection and autonomic dysfunction. Auton. Neurosci. Basic Clin. 2022;242:103018. doi: 10.1016/j.autneu.2022.103018. - DOI - PubMed
    1. Kennedy P.G.E. The Spectrum of Neurological Manifestations of Varicella-Zoster Virus Reactivation. Viruses. 2023;15:1663. doi: 10.3390/v15081663. - DOI - PMC - PubMed
    1. Gershon A.A., Gershon M.D., Shapiro E.D. Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster. J. Infect. Dis. 2021;224((Suppl. S2)):S387–S397. doi: 10.1093/infdis/jiaa573. - DOI - PMC - PubMed